Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
synthetic lethality
Biotech
BeiGene inks $150M deal to follow cancer trail blazed by Amgen
BeiGene has struck a $150 million deal to license an asset from CSPC, clearing it to explore a combination that has attracted the interest of Amgen.
Nick Paul Taylor
Dec 13, 2024 9:11am
Tango axes PRMT5 inhibitor, shifts focus to 2 sibling molecules
Nov 6, 2024 8:28am
Repare lays off 25% of staff as biotech halts preclinical R&D
Aug 29, 2024 6:36am
Ideaya bags option on Biocytogen bispecific ADC in $400M deal
Jul 31, 2024 9:04am
Tango drops USP1 inhibitor over liver toxicity in phase 1 trial
May 23, 2024 8:11am
Roche axes Repare's oncology drug days after starting study
Feb 13, 2024 5:51am
